Safety, Tolerability and Pharmacokinetics of AD16 Tablets After MAD in Healthy Chinese Adult Subjects (MAD)
Safety, Tolerability and Pharmacokinetics of AD16 Tablets After Multiple Administration in Healthy Chinese Adult Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Changsha, China
- The Central South University Xiang Ya Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy subjects were aged 18-45 years (including boundary values), male and female.
- Weight ≥50kg (male) or ≥45kg (female), and body mass index (BMI) of 19-24kg/m2 (including the boundary values at both ends).
- Have fully understood this study, voluntarily participated in it, and signed the Informed Consent.
- Subjects are able to communicate well with researchers and complete the study according to protocol.
- The subjects were deemed to be in good health based on physical examination, medical history, vital signs, electrocardiogram, chest X-ray, abdominal ultrasound, and laboratory tests.
- Subject (including partner) is willing to have no pregnancy plan for the next 30 days (female subject) or 90 days (male subject) and is willing to use effective contraception.
Exclusion Criteria:
- Positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody or HIV antibody.
- The patient has symptoms or related history of any serious disease, including but not limited to heart, liver, kidney, or other acute or chronic digestive tract or respiratory tract diseases, as well as diseases of the blood, endocrine, neurological, psychiatric and other systems, or any other disease or physiological condition that can interfere with the study results.
- A history of postural hypotension with frequent episodes.
- A history of frequent nausea or vomiting due to any cause.
- Any clear history of drug or food allergies, especially allergies to ingredients similar to the drugs in this study.
- Have special dietary requirements and cannot comply with the uniform diet provided by the clinical research center.
- Previous drug abuse history or positive urine drug screening during screening period.
- Smokers who smoked more than 5 cigarettes a day in the 3 months before the test.
- Heavy drinkers or regular drinkers in the 6 months prior to the study screening, who drank more than 14 units of alcohol per week (1 unit of alcohol ≈360 mL beer or 45 mL 40% spirits or 150 mL wine) or had a positive alcohol breath test during the screening period.
- Excessive consumption of tea, coffee (more than 6 cups) and/or caffeinated beverages (more than 1L) per day.
- Take food or drink rich in xanthine, grapefruit or alcohol, caffeine (e.g., dragon fruit, mango, grapefruit, chocolate, coffee or tea) within 48 hours before administration.
- Surgical procedures, transfusions of blood or blood components in the month prior to study screening.
- Blood loss or donation of more than 400 mL in the 2 months prior to screening.
- Participated in other clinical studies and took experimental drugs within 3 months prior to study screening.
- Study participants who had received any medication in the 28 days prior to screening.
- Pregnant or lactating women or women who have had unprotected sex within 14 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AD16
AD16 tablets should be administered only in the morning on the day of the first dose and on the ninth day after the first dose.
Fasting is required for at least 10 h before administration.Two dosing cohorts received AD16 From the third day to the eighth day, the medicine was administered twice a day, 1 h before breakfast, 1 h before dinner or 2 h after dinner, with a 12 h interval (time window ±1 h).The duration of oral AD16 tablets was nine days.
|
AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
|
|
Placebo Comparator: AD16 placebo
AD16 placebo tablets should be administered only in the morning on the day of the first dose and on the ninth day after the first dose.
Fasting is required for at least 10 h before administration.Two dosing cohorts received AD16 placebo From the third day to the eighth day, the medicine was administered twice a day, 1 h before breakfast, 1 h before dinner or 2 h after dinner, with a 12 h interval (time window ±1 h).The duration of oral AD16 placebo tablets was nine days.
|
AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events
Time Frame: day-7 to day11
|
The number of adverse events
|
day-7 to day11
|
|
Serious adverse events
Time Frame: day-7 to day11
|
The number of serious adverse events
|
day-7 to day11
|
|
Number of participants with abnormal laboratory test results
Time Frame: Screening period (day-7 to day-2) and day11
|
Laboratory tests include Blood routine, blood biochemistry, coagulation function and urine routine, etc.
|
Screening period (day-7 to day-2) and day11
|
|
Number of participants with abnormal vital signs
Time Frame: Screening period(day-7 to day-1)、days1、4、5、6、8、9
|
Pulse, blood pressure, body temperature and respiratory rate were observed at different time points before and after medication.
|
Screening period(day-7 to day-1)、days1、4、5、6、8、9
|
|
Number of participants with abnormal 12-lead electrocardiogram readings
Time Frame: Screening period(day-7 to day-2)、days1、6、11
|
Abnormal12-lead electrocardiogram
|
Screening period(day-7 to day-2)、days1、6、11
|
|
Number of participants with abnormal physical examination findings
Time Frame: Screening period(day-7 to day-2)、days11
|
The skin, mucosa, lymph nodes, head, neck, chest, abdomen, spine/limbs and nervous system were observed at different time points before and after medication.
|
Screening period(day-7 to day-2)、days11
|
|
Concomitant medication
Time Frame: Up to day 11
|
Any concomitant medication
|
Up to day 11
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tmax of AD16
Time Frame: Up to day 11
|
Time to reach the maximum (peak) plasma concentration following drug administration
|
Up to day 11
|
|
Cmax of AD16
Time Frame: Up to day 11
|
Maximum (peak) plasma drug concentration
|
Up to day 11
|
|
t1/2z of AD16
Time Frame: Up to day 11
|
Elimination half-life (to be used in a one-compartment or noncompartmental model)
|
Up to day 11
|
|
AUC 0-∞ of AD16
Time Frame: Up to day 11
|
Area under the plasma concentration-time curve(AUC) from time zero to infinity
|
Up to day 11
|
|
AUC 0-t of AD16
Time Frame: Up to day 11
|
Area under the plasma concentration-time curve(AUC) from time zero to time t
|
Up to day 11
|
|
Vd/F of AD16
Time Frame: Up to day 11
|
Apparent volume of distribution after non-intravenous administration
|
Up to day 11
|
|
CL/F of AD16
Time Frame: Up to day 11
|
CL/F is defined as the ratio of total clearance(CL) to bioavailability(F).
|
Up to day 11
|
|
λz of AD16
Time Frame: Up to day 11
|
Terminal disposition rate constant/terminal rate constant
|
Up to day 11
|
|
AUC 0-48h of AD16
Time Frame: Up to day 11
|
Area under the plasma concentration-time curve from time zero to time 48h
|
Up to day 11
|
|
AUC_%Extrap of AD16
Time Frame: Up to day 11
|
AUC_%Extrap is residual area percentage
|
Up to day 11
|
|
Tmax,ss of AD16
Time Frame: Up to day 11
|
Time to reach the maximum (peak) plasma concentration following drug administration at steady state
|
Up to day 11
|
|
Cmax, ss of AD16
Time Frame: Up to day 11
|
Maximum (peak) steady-state plasma drug concentration during a dosage interval
|
Up to day 11
|
|
Cavg,ss of AD16
Time Frame: Up to day 11
|
Cavg,ss is the steady-state mean concentration
|
Up to day 11
|
|
t1/2,ss of AD16
Time Frame: Up to day 11
|
Elimination half-life(steady state )
|
Up to day 11
|
|
AUC 0-τ,ss of AD16
Time Frame: Up to day 11
|
The area under the plasma concentration-time curve during a dosing interval at steady state
|
Up to day 11
|
|
AUC 0-48h,ss of AD16
Time Frame: Up to day 11
|
Area under the plasma concentration-time curve from the last dose to 48 h
|
Up to day 11
|
|
AUC 0-∞,ss of AD16
Time Frame: Up to day 11
|
The area under the plasma concentration-time curve is extrapolated from the last dose to infinity
|
Up to day 11
|
|
CL/F,ss of AD16
Time Frame: Up to day 11
|
CL/F is defined as the ratio of total clearance(CL) to bioavailability(F)(steady state )
|
Up to day 11
|
|
Rac of AD16
Time Frame: Up to day 11
|
Rac is accumulation ratio
|
Up to day 11
|
|
DF of AD16
Time Frame: Up to day 11
|
Degree of fluctuation(DF)Percentage fluctuation in steady state = 100 × (Cmax,ss -Cmin,ss)/Cavg,ss
|
Up to day 11
|
|
Vd/F,ss of AD16
Time Frame: Up to day 11
|
Apparent volume of distribution after non-intravenous administration (steady state )
|
Up to day 11
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SCCIP-AD16-2018-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.